Pembrolizumab,Trastuzumab,Zolbetuximab,Nivolumab,Ipilimumab,Tislelizumab,oxaliplatin,capecitabine
Merck,astellas,BMS,Beigene,roche
[]
a pivotal hit for claudin18.2, but biomarker diagnosis is essential. quick take on the #gi23 abstract just published, via $alpmy
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.